Weight and Healthcare

with Ragen Chastain
  • ٤٫٠ (٢١)
  • طب
  • مرتان في الأسبوع

Examining the intersections of weight science, weight stigma, and healthcare and what evidence, ethics, and lived experience teach us about healthcare and public health best practices for higher-weight people. weightandhealthcare.substack.com

  1. قبل يومين

    Quick Guide - Weight-Centric vs Weight-Inclusive Paradigm (Reader Question)

    I received a question from reader Brit who said “I see you and other people talking and writing about the weight-inclusive and weight-centric (and sometimes weight-neutral and weight-loss paradigm). I think I know what they mean but could you give a quick explanation? I’m happy to Brit, sometimes it’s good to go back to basics! Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ٤ من الدقائق

  2. قبل ٥ أيام

    Applying Lancet Commission's Concerning Ideas in the Real World - Part 2

    In Part 1 we began discussing the article “Implications of a New Ob*sity Definition Among the All of Us Cohort” by Fourman et al. This is a study that took the recommendations of the (heavily financially entangled with the weight loss industry) Lancet Commission around increasing the methods by which “ob*sity” can be “diagnosed” (the massive issues with which I wrote about here,) and applied it to the All of Us population. So what did they find? Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ٨ من الدقائق

  3. ٣ ديسمبر

    Applying Lancet Commission's Concerning Ideas in the Real World - Part 1

    I previously wrote about a Lancet Commission that published what I would describe as an opinion piece that they attempted to disguise as legitimate science. In it, they manipulated multiple research processes in order to create the largest possible market for the weight loss industry (in which the authors had massive financial entanglements) by wildly expanding the ways that someone might be “diagnosed” as “ob*se.” You can read about the whole sordid affair here. This has been a longtime goal of the weight loss industry and this group of financially entangled authors made it real, at least in their article. Now another group of authors have shown the reality if these ideas are applied in the real world. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ٧ من الدقائق

  4. ٢٢ نوفمبر

    Dealing with Diet Culture and Weight Stigma at the Holidays Part 1

    Today I’m taking a break from talking about weight and healthcare to write about navigating so much of the nonsense that happens during the holiday season. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ٩ من الدقائق

  5. ١٥ نوفمبر

    Calculating the supposed "cost of obesity" - Part 1

    Today will be the first post in a short series discussing attempts to “calculate” the (supposed) “costs” of “ob*sity.” Before we get into any of this I want to say unequivocally that anytime we try to calculate the cost of a group of people, including and especially, to support a call for their eradication, we are going down a very bad, very wrong road. So while I will be discussing the specific issues with these calculations, please always remember that the calculations shouldn’t be undertaken in the first place. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ٩ من الدقائق

  6. ١٢ نوفمبر

    GLP-1s and Muscle Mass Part 3 - Dubious Claims

    In Part 1 we looked at the basics and early research around GLP-1s for weight loss and muscle loss. In part 2 we looked at recent research around the newest GLP-1 weight loss drugs, tirzepatide (Zepbound) and semaglutide (Wegovy). In this final part of the series we are going to talk about the justifications/excuses/spin that are happening around the loss of lean muscle mass on GLP-1s. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ٨ من الدقائق

  7. ٨ نوفمبر

    GLP-1s and Muscle Loss - Part 2 Wegovy and Zepbound

    In Part 1 we looked at an early study of GLP1 drugs and muscle loss. Today we’ll look at two more recent studies, one for Eli Lilly’s drug tirzepatide and one for Novo Nordisk’s drug semaglutide. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ١٠ من الدقائق

  8. ٥ نوفمبر

    GLP-1s and Muscle Loss - Part 1 The Basics

    As GLP-1 drugs get heavily marketed for weight loss, we know that when people stop taking the drugs they experience rapid weight regain. We also know that, while the claim is that if people stay on the drugs forever they’ll maintain the weight loss, there isn’t any research proving that and that in the longest study of these drugs for weight loss (4 years) they lost 89.5% of the sample. There is another aspect that I think is not being discussed nearly enough and that is the subject of how much of the weight that is lost is coming from what is known as lean body mass. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

    ٩ من الدقائق
مشاهدة الكل (٢٤٣)

٤
من ٥
‫٢١ من التقييمات‬

حول

Examining the intersections of weight science, weight stigma, and healthcare and what evidence, ethics, and lived experience teach us about healthcare and public health best practices for higher-weight people. weightandhealthcare.substack.com

المعلومات

  • صناع العمل
    with Ragen Chastain
  • سنوات النشاط
    ٢٠٢٣ - ٢٠٢٥
  • الحلقات
    ٢٤٣
  • التقييم
    ملائم
  • حقوق النشر
    © Ragen Chastain
  • موقع البرنامج على الويب
    Weight and Healthcare

قد يعجبك أيضًا